Exhibit 10.102
| | | | | | | | | | | | | | | | | | |
UNIVERSITY OF CALIFORNIA, IRVINE | |  | | UCI |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BERKELEY DAVIS IRVINE LOS ANGELES RIVERSIDE SAN DIEGO SAN FRANCISCO | | SANTA BARBARA |
| SANTA CRUZ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | |
| Office of Technology Alliances | | | | | | OFFICE: 949.824.7295 |
380 University Tower Irvine, CA 92697-7700 | | | | | | FAX: 949.824.2899 |
| | | | | | |
| IN DUPLICATE | | June 1, 2007 |
Roger G. Stoll, Ph.D.
Chairman, President & Chief Executive Officer
Cortex Pharmaceuticals, Inc.
15231 Barranca Parkway
Irvine, CA 92618
Re:Amendment to Exclusive License Agreement -UC Control No. 93-04-0412
Dear Dr. Stoll:
In response to your recent request, this letter documents our agreement and provides an amendment to the above-referenced License Agreement with respect to the diligence requirements.
In view of your report to us regarding Cortex’s progress on and investment in the AMPAKINE® program, the diligence deadline in Section 7.4 of the License Agreement relating to the filing of a New Drug Application, or its equivalent in a foreign country, is hereby extended from October 11, 2007, to October 10, 2012. Please sign this letter and the duplicate original in the spaces provided below and return them to me. You will receive one fully processed original in the mail shortly.
|
| Sincerely, |
|
|
David G. Schetter, |
Assistant Vice Chancellor |
| | | | | | | | |
| Agreed: | | | | | | |
| | |
| CORTEX PHARMACEUTICALS, INC. | | | | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| | | | |
| By: | | /s/ Roger Stoll | | | | By: | | /s/ David Schetter |
| | Roger Stoll, Ph.D., President, and Chief Executive Officer | | | | | | David G. Schetter Assistant Vice Chancellor |
| | Date: June 1, 2007 | | | | | | Date: June 1, 2007 |
